Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) PT at $15.33

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $15.3333.

A number of brokerages have weighed in on COYA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. Roth Capital started coverage on Coya Therapeutics in a report on Friday, June 5th. They set a “buy” rating and a $12.00 price target on the stock. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Friday, June 12th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Friday, April 10th. Finally, Wall Street Zen lowered shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Prosperity Wealth Management Inc. grew its stake in shares of Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares during the period. JPMorgan Chase & Co. bought a new position in Coya Therapeutics in the third quarter worth approximately $28,000. Cetera Investment Advisers boosted its holdings in Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after acquiring an additional 8,000 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new stake in Coya Therapeutics in the fourth quarter valued at approximately $47,000. Finally, Occudo Quantitative Strategies LP bought a new stake in shares of Coya Therapeutics during the fourth quarter valued at approximately $66,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Stock Performance

Shares of NASDAQ COYA opened at $4.19 on Monday. The company’s 50 day moving average price is $4.89 and its 200-day moving average price is $4.66. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75. The company has a market capitalization of $98.30 million, a P/E ratio of -3.64 and a beta of 0.61.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.15 million. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. Analysts forecast that Coya Therapeutics will post -1.49 earnings per share for the current year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.